profit from every ₹100 of sales.
₹0₹100
Piramal Pharma
₹244.54-0.22% today
+46.9% in 1 year
1-year low ₹133.271-year high ₹246.37
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Piramal Pharma sold, what it kept, and what it did with the cash.
Sales went from ₹70.3 billion in 2023 to ₹88.7 billion in 2026, with -₹3.26 billion of profit last year.
SalesProfit
Piramal Pharma handed back 2% of the cash it generated last year.
₹186M
Free cash flow 2026₹7.6B
Bought back its own shares–
Paid as dividends₹186M
Cash vs. debt₹12.0B vs. ₹56.7B
Piramal Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Piramal Pharma | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Piramal Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 70,324 | 81,064 | 91,512 | 88,691 | |
| 40,322 | 48,477 | 59,195 | 56,305 | |
| -480 | 4,620 | 6,285 | 904 | |
| 8,943 | 13,668 | 16,526 | 9,960 | |
| -1,865 | 178 | 911 | -3,259 | |
| -1.54 | 0.14 | 0.68 | -2.46 | |
| 57.3% | 59.8% | 64.7% | 63.5% | |
| -0.7% | 5.7% | 6.9% | 1.0% | |
| -2.7% | 0.2% | 1.0% | -3.7% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 145,226 | 153,118 | 156,776 | 179,650 |
| Cash | 1,956 | 3,568 | 3,690 | 11,999 |
| Total debt | 56,371 | 47,102 | 48,565 | 56,746 |
| Total liabilities | 77,491 | 74,004 | 75,521 | 98,024 |
| 67,735 | 79,113 | 81,254 | 81,626 | |
| 1,213 | 1,284 | 1,340 | 1,325 | |
| 1.3% | 3.7% | 4.8% | 0.9% | |
| -2.8% | 0.2% | 1.1% | -4.0% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 4,839 | 10,045 | 8,923 | 16,526 | |
| 9,648 | 7,120 | 6,644 | 8,900 | |
| -4,809 | 2,925 | 2,279 | 7,626 | |
| Dividends paid | 670 | – | 145 | 186 |
| – | – | – | – | |
| 0 | 275 | 480 | 417 |
Valuation
- –
- –
- –
- 2.6×
- 3.7×
- 42.5×
- 37.1×
- 2.4%
- -1.0%
- 0.1%
Profitability
- 63.5%
- 1.0%
- -3.7%
- –
- 0.9%
- 2.7%
- –
- –
- –
- –
Growth
- +8.0%
- –
- –
- –
- +3.0%
Financial health
- 4.5×
- 0.70
- –
- 0.5×
- 1.51
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 35%of 952
Bottom 27%of 884
Bottom 42%of 886
Top 40%of 987
0.1%of the share price, paid each year
On $1,000 invested$1a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
: 2.4%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
18No pass
Benjamin Graham
28No pass
Philip Fisher
29No pass
Peter Lynch
37No pass
Joel Greenblatt
0No pass
Charlie Munger
19No pass
Terry Smith
18No pass
Questions about Piramal Pharma
Is Piramal Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Piramal Pharma AI analysis
What does Piramal Pharma do?
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It is in Drug Manufacturers - Specialty & Generic, based in Mumbai, India.
Does Piramal Pharma pay a dividend?
Yes. At today's price the dividend is 0.1% a year. In 2026 it paid out ₹186 million in dividends.
Is Piramal Pharma stock halal?
Yes. Piramal Pharma passes our halal screen: its business is permitted and its debt is 17% of its market value, under the 30% limit. How we check
How has Piramal Pharma stock done over the past year?
Up 46.9% over the past twelve months, to ₹244.54. It traded between ₹133.27 and ₹246.37, close to its high.
Who are Piramal Pharma's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Piramal Pharma's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.